Muderris Togay, Yar Sağlam Atiye Seda, Unsal Döndü, Mülazimoğlu Selçuk, Sevil Ergün, Kayhan Handan
Department of Otorhinolaryngology, Head and Neck Surgery, Izmir Bakircay University Faculty of Medicine, 35610 Izmir, Turkey.
Department of Medical Biology and Genetics, Gazi University Faculty of Medicine, 06500 Ankara, Turkey.
Exp Ther Med. 2022 Jan;23(1):40. doi: 10.3892/etm.2021.10962. Epub 2021 Nov 12.
Age-related hearing loss (ARHL) is a major public health concern, which is characterized by gradual, progressive sensorineural hearing loss and deterioration of sound localization, with no effective treatment available to date. The aim of the present study was to evaluate the efficacy of resveratrol to prevent and treat ARHL. For this purpose, 32 male C57BL/6 mice were assigned to four groups: Early treatment, late treatment, control and sham control. The experiment lasted for 15 months. Treatment was started at three months of age in the early treatment group and at sixth months in the late treatment group. The auditory brainstem response test was performed once every three months. At the end of the study period, and levels in the cochlear tissues of the animals were analyzed by reverse transcription-quantitative PCR. Hearing thresholds of the mice in the early treatment group were better than those in the other groups (P<0.001) at the end of the study. However, hearing levels in the late treatment group were not significantly different from those in the control groups (P>0.05), although mean thresholds were lower. The threshold shift in the early treatment group was significantly lower at all frequencies when compared with those in the control groups (P<0.001). The mRNA expression levels of pro-apoptotic genes and were lower (P<0.05), anti-apoptotic genes and were higher (P<0.05), and as genes that have a role in inflammation and and as genes with a vital role in apoptosis were lower (P<0.05) in the early treatment group when compared with the late treatment and control groups. These results suggested that resveratrol is effective in the prevention of ARHL, particularly when started prior to the beginning of hearing loss.
年龄相关性听力损失（ARHL）是一个重大的公共卫生问题，其特征为渐进性的感音神经性听力损失以及声音定位能力的衰退，迄今为止尚无有效的治疗方法。本研究的目的是评估白藜芦醇预防和治疗ARHL的疗效。为此，将32只雄性C57BL/6小鼠分为四组：早期治疗组、晚期治疗组、对照组和假手术对照组。实验持续15个月。早期治疗组在3月龄开始治疗，晚期治疗组在6月龄开始治疗。每三个月进行一次听性脑干反应测试。在研究期结束时，通过逆转录定量PCR分析动物耳蜗组织中的 和 水平。在研究结束时，早期治疗组小鼠的听力阈值优于其他组（P<0.001）。然而，晚期治疗组的听力水平与对照组相比无显著差异（P>0.05），尽管平均阈值较低。与对照组相比，早期治疗组在所有频率下的阈值变化均显著更低（P<0.001）。与晚期治疗组和对照组相比，早期治疗组中促凋亡基因 和 的mRNA表达水平更低（P<0.05），抗凋亡基因 和 更高（P<0.05），作为在炎症中起作用的基因 和 以及在凋亡中起关键作用的基因 和 更低（P<0.05）。这些结果表明，白藜芦醇对预防ARHL有效，尤其是在听力损失开始之前就开始使用时。
